Japan Nods Include Torii's Vtama, Skyrizi In New Uses

Concomitant Use Rules Also Revised

Jun 06 2024

Listen to this article

Japan issues approval recommendations in new indications, including Torii's Vtama in atopic dermatitis and AbbVie's Skyrizi in ulcerative colitis. Separately, filing requirements for the use of concomitant therapies have been revised.

Japan cautiously eased approval process for concomitant therapeutics used in combination therapy. • Source: Shutterstock

An advisory committee to Japan’s Ministry of Health, Labour and Welfare (MHLW) has issued approval recommendations for a new batch of drugs including Dermavant Sciences Inc./JT Pharmaceuticals Inc/Torii Pharmaceutical Co. Ltd.’s Aryl hydrocarbon receptor (AhR) Vtama (tapinarof) for psoriasis vulgaris and atopic dermatitis, the latter being the global-first approval in this indication.

Other notable products receiving preliminary nods on 31 May included Novo Nordisk A/S’s Awiqli (once-weekly basal insulin icodec) for...

Easing Market Entry: Japan’s PMDA Allows Approval Filings In English

Sep 12 2024

• By Lisa Takagi

Non-Japanese firms without offices in the country may submit documents for approval filings in English, subject to certain conditions.

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

Sep 12 2024

• By Sue Sutter

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

Progress Or Hype? Looking At A Decade Of Cell Therapy In Japan

Aug 26 2024

• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting reimbursement prices. How has the sector panned out over the last decade?

Japan Recommends Donanemab, Sets Raft Of New And Reduced Prices

Aug 14 2024

• By Lisa Takagi

A Japanese approval for Lilly's Alzheimer's drug donanemab is expected soon following a positive recommendation from the MHLW. The ministry has also announced reimbursement prices for 12 new products including Fabhalta, along with price cuts for Tezspire, Dupixent and competitors following a review.